Farallon Capital Management, L.L.C. reported 73 positions worth $14.94B for the quarter ended Jun 30, 2026, up 1.5% on the prior quarter. It opened 16 new positions, added to 26, trimmed 22 and exited 98. Its largest holding is Revolution Medicines, Inc. at 17% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| IMVT Immunovant, Inc. | +4.26M | +275.5% | $164.10M | 1.5% |
| ROIV Roivant Sciences Ltd. | +4.63M | +47.9% | $164.00M | 3.39% |
| BSX Boston Scientific Corp | +3.05M | +40.8% | $130.20M | 3.01% |
| BBIO BridgeBio Pharma, Inc. | +1.38M | +14.7% | $102.60M | 5.36% |
| TNGX Tango Therapeutics, Inc. | +3.18M | +35.0% | $99.39M | 2.57% |
| NVO Novo Nordisk A S | +1.84M | +234.9% | $88.07M | 0.84% |
| BIDU Baidu, Inc. | +760.0K | +171.3% | $86.86M | 0.921% |
| TMO Thermo Fisher Scientific Inc. | +167.7K | +19.0% | $84.08M | 3.52% |
| ACHC Acadia Healthcare Company, Inc. | +2.48M | +143.0% | $73.35M | 0.834% |
| TWST Twist Bioscience Corp | +708.8K | +49.6% | $72.92M | 1.47% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| MSFT Microsoft Corp | -1.23M | -52.5% | $459.53M | 2.78% |
| AMZN Amazon Com Inc | -1.59M | -37.6% | $377.86M | 4.2% |
| AON Aon plc | -1.13M | -45.0% | $374.83M | 3.07% |
| SCHW Schwab Charles Corp | -3.96M | -100.0% | $371.75M | Exited |
| GOOG Alphabet Inc. | -996.2K | -100.0% | $285.78M | Exited |
| NTRA Natera, Inc. | -989.0K | -30.8% | $268.46M | 4.03% |
| V Visa Inc. | -840.7K | -100.0% | $254.10M | Exited |
| AVGO Broadcom Inc. | -627.7K | -35.3% | $237.11M | 2.91% |
| DIS Walt Disney Co | -2.40M | -100.0% | $231.47M | Exited |
| UNH Unitedhealth Group Inc | -551.2K | -30.3% | $229.08M | 3.53% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| PBLS Parabilis Medicines, Inc. | +2.37M | $64.82M | 0.434% |
| NVS Novartis Ag | +363.0K | $56.89M | 0.381% |
| WRBY Warby Parker Inc. | +828.0K | $25.12M | 0.168% |
| KLRA Kailera Therapeutics, Inc. | +1.10M | $24.23M | 0.162% |
| AXTA Axalta Coating Systems Ltd. | +478.0K | $16.36M | 0.109% |
| BIIB Biogen Inc. | +71.0K | $15.34M | 0.103% |
| TSHA Taysha Gene Therapies, Inc. | +2.25M | $15.32M | 0.103% |
| ALMR Alamar Biosciences, Inc. | +462.9K | $12.54M | 0.084% |
| IFRX InflaRx N.V. | +3.33M | $7.45M | 0.05% |
| SMG Scotts Miracle-Gro Co | +88.0K | $5.99M | 0.04% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| SCHW Schwab Charles Corp | -3.96M | $371.75M | 2.53% |
| GOOG Alphabet Inc. | -996.2K | $285.78M | 1.94% |
| V Visa Inc. | -840.7K | $254.10M | 1.73% |
| DIS Walt Disney Co | -2.40M | $231.47M | 1.57% |
| MA Mastercard Inc | -435.1K | $217.39M | 1.48% |
| MCK Mckesson Corp | -234.3K | $202.75M | 1.38% |
| TYRA Tyra Biosciences, Inc. | -3.58M | $137.15M | 0.932% |
| THC Tenet Healthcare Corp | -452.2K | $85.33M | 0.58% |
| CAH Cardinal Health Inc | -368.0K | $77.76M | 0.528% |
| PCVX Vaxcyte, Inc. | -1.26M | $73.28M | 0.498% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | RVMD Revolution Medicines, Inc. | Healthcare | 13.55M | $2.54B | 16.99% | -54.0K | -0.4% | Reduced | 6.32% |
| 2 | BBIO BridgeBio Pharma, Inc. | Healthcare | 10.74M | $800.14M | 5.36% | +1.38M | +14.7% | Added | 5.49% |
| 3 | PTGX Protagonist Therapeutics, Inc | Healthcare | 6.35M | $778.25M | 5.21% | 0 | 0.0% | Unchanged | 9.63% |
| 4 | EXEL Exelixis, Inc. | Healthcare | 13.47M | $732.79M | 4.9% | +357.0K | +2.7% | Added | 5.21% |
| 5 | LQDA Liquidia Corp | Healthcare | 8.37M | $666.94M | 4.46% | -291.0K | -3.4% | Reduced | 9.39% |
| 6 | AMZN Amazon Com Inc | Consumer Discretionary | 2.63M | $627.55M | 4.2% | -1.59M | -37.6% | Reduced | 0.02% |
| 7 | LNTH Lantheus Holdings, Inc. | Healthcare | 5.58M | $619.43M | 4.15% | 0 | 0.0% | Unchanged | 8.56% |
| 8 | NTRA Natera, Inc. | Healthcare | 2.22M | $602.18M | 4.03% | -989.0K | -30.8% | Reduced | 1.54% |
| 9 | UNH Unitedhealth Group Inc | Healthcare | 1.27M | $528.07M | 3.53% | -551.2K | -30.3% | Reduced | 0.14% |
| 10 | TMO Thermo Fisher Scientific Inc. | Healthcare | 1.05M | $526.02M | 3.52% | +167.7K | +19.0% | Added | 0.28% |
| 11 | ROIV Roivant Sciences Ltd. | Healthcare | 14.31M | $506.40M | 3.39% | +4.63M | +47.9% | Added | 1.98% |
| 12 | AON Aon plc | Financial Services | 1.38M | $458.58M | 3.07% | -1.13M | -45.0% | Reduced | 0.65% |
| 13 | BSX Boston Scientific Corp | Healthcare | 10.52M | $449.04M | 3.01% | +3.05M | +40.8% | Added | 0.72% |
| 14 | AVGO Broadcom Inc. | Technology | 1.15M | $435.09M | 2.91% | -627.7K | -35.3% | Reduced | 0.02% |
| 15 | MSFT Microsoft Corp | Technology | 1.11M | $415.12M | 2.78% | -1.23M | -52.5% | Reduced | 0.01% |
Tip. Select a row to see that position’s full history at Farallon Capital Management, L.L.C.
As of its Q2 2026 13F filing, Farallon Capital Management, L.L.C.’s five largest positions were Revolution Medicines, Inc. (RVMD) at 17.0%, BridgeBio Pharma, Inc. (BBIO) at 5.4%, Protagonist Therapeutics, Inc (PTGX) at 5.2%, Exelixis, Inc. (EXEL) at 4.9%, Liquidia Corp (LQDA) at 4.5% of the reported portfolio.
Farallon Capital Management, L.L.C. reported a 13F portfolio worth $14.94B across 73 positions for Q2 2026. That is up 1.5% from the previous quarter.
Its largest purchases by value were Immunovant, Inc. ($164.10M), Roivant Sciences Ltd. ($164.00M), Boston Scientific Corp ($130.20M). It opened 16 new positions.
Its largest sales by value were Microsoft Corp ($459.53M), Amazon Com Inc ($377.86M), Aon plc ($374.83M). It exited 98 positions entirely.
From the Form 13F-HR reports Farallon Capital Management, L.L.C. files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.